Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR Exon 20–Mutant NSCLC.
|Videos|July 12, 2016
- Gastrointestinal Cancers: mCRC (Issue 9)
- Volume 1
- Issue 9
Role of DPR in Colorectal Cancer
Author(s)Volker Heinemann, MD, PhD
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.
Advertisement
Articles in this issue
about 10 years ago
Overview of the Lume 1 and 2 Trialsabout 10 years ago
Impact of HER2 Amplification in Colorectal Cancerabout 10 years ago
Novel Immunotherapy Combinations on Horizon for mCRCabout 10 years ago
SIRT Added to First-line Chemo Improves Response in Colorectal CancerAdvertisement
Related to this article
Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.
Adding subcutaneous epcoritamab to R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
The ADC rinatabart sesutecan showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer with a tolerable safety profile.
A cisplatin patch achieves 95.5% complete responses in early oral lesions, helping patients avoid surgery with durable control and minimal systemic toxicity.
The RASolute 309 trial is investigating frontline daraxonrasib plus the RAS G12D inhibitor zoldonrasib vs chemotherapy in advanced pancreatic ductal adenocarcinoma.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
4
Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL
5